FDA panel considers a first-of-its-kind flu vaccine using mRNA technology (opens original article in a new tab)

U.S. health advisers are evaluating Moderna's mRNA flu vaccine, which showed 27% effectiveness in reducing cases among adults 50 and older, with FDA noting no safety issues but incomplete data on vulnerable groups.

• FDA advisory committee is reviewing Moderna's mRNA flu vaccine for approval
• mFlusiva showed 27% reduction in flu cases among 50+ adults in a 40,000-person study
• FDA noted no safety concerns but lacks data on frail older adults and immunocompromised individuals